GeneThera Inc. Expands Its Operation in the United Kingdom
GeneThera has established a new subsidiary in the UK, GeneThera Robotics Ltd, to manage UK and international operations. This move supports the development of the Zoonotic Infectious Diseases Alert Shield (ZIDAS) network, utilizing advanced Molecular Robotic and AI technology. The subsidiary will implement a dual laboratory system for high-throughput assays and wastewater testing for SARS-CoV-2. CEO Dr. Tony Milici emphasized the UK's promising market, particularly for detecting the B.1.1.7 variant. Mrs. Alex Baglietto has been appointed Managing Director, bringing extensive experience in government relations.
- Establishment of a UK subsidiary, enhancing international operations.
- Development of ZIDAS, a comprehensive infectious disease alert network.
- Opportunity to address the B.1.1.7 SARS-CoV-2 variant through advanced testing.
- Appointment of a qualified Managing Director with relevant experience.
- None.
WESTMINSTER, Colo., May 18, 2021 (GLOBE NEWSWIRE) -- GeneThera is pleased to announce that it has incorporated a subsidiary in the United Kingdom. GeneThera Robotics Ltd, a majority owned subsidiary based in England, will be responsible for UK and International Operations. Mrs. Alex Baglietto has been appointed as Managing Director of GeneThera Robotics Limited. GeneThera Robotics is the first step of a global network of laboratories which will create the infrastructure of the Zoonotic Infectious Diseases Alert Shield (ZIDAS). ZIDAS, a network built on Molecular Robotic and AI technology (MORAP), is based on the development of two laboratory settings. The first, a stationary robotic lab facility designed for ultra-high throughput assay, genomic DNA sequencing and viral molecular therapeutics. The second, a mobile lab unit platform, designed to test wastewater for the presence of SARS-CoV-2 in communities worldwide.
Dr. Tony Milici, Chairman and CEO of GeneThera Inc., commented: “We have decided to expand our operation to the UK because we see great opportunities both at the government and private sector level. The UK has been at forefront of the COVID-19 pandemic. The B.1.1.7 SARS CoV-2 British variant has proven to be of particular importance with an estimated transmission rate between forty to eighty percent more transmissible than the wild-type SARS-CoV-2 virus. Cases of B.1.1.7 variant are most likely to be under reported, if reported at all, as common tests are not able to differentiate this variant from other SARS-CoV-2 variants. We believe that our technology platform can significantly help in the detection of this variant by testing wastewater samples. Additionally, the appointment of Mrs. Baglietto, will prove to be a tremendous asset, as she has experience in business and government relations, communications, and in assisting clients in scaling-up business operations, and increasing inward investments."
Mrs. Baglietto holds a B.A. and an M.A. from Cal State University at San Bernardino. She has worked both in the private and public sector and has experience dealing with government and business relations, clients, communications and investments. Mrs. Baglietto has worked with numerous private and public companies, most recently, assisting with assessing political risk, international trade investments and ministry of finance guarantees. Mrs. Baglietto stated, “I am extremely excited to be a part of such a promising and potentially life-saving company. I am aware of the challenges ahead and will utilize my strengths to propel the company forward. I have no doubt that similarly to COVID-19, humanity will continue to see the rise of other infectious diseases; GeneThera will be at the forefront of new COVID variants and other diseases.”
GeneThera has likewise entered into a partnership agreement with Cumming Corporation, a privately held international consulting firm. Cumming Corporation will provide consulting support related to the building of laboratory facilities in the UK, as a part of GeneThera’s ZIDAS global network strategy.
About GeneThera, Inc.
GeneThera is a biotechnology company developing molecular robotic/AI diagnostics and therapeutics in an effort to control and eradicate zoonotic diseases. GeneThera developed molecular assays for BSE and Mycobacterium Avium Paratuberculosis (MAP). MAP is an infectious organism causing Paratuberculosis in dairy cows that is also linked to Crohn’s Disease in humans. We utilize these technologies to minimize the spread of animal infectious organisms such as SARS-CoV-2 to humans. Management and prevention of zoonotic diseases is crucial to human and animal health on a global scale.
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
For further information, please contact:
Tony Milici MD, PhD
GeneThera, Inc.
(720) 587-5100
FAQ
What is the purpose of GeneThera's new subsidiary in the UK?
Who has been appointed Managing Director of GeneThera Robotics Ltd?
How will GeneThera's technology help in detecting COVID-19 variants?
What is ZIDAS, and how is it related to GeneThera's operations?
What partnership has GeneThera entered into for its operations in the UK?
